Implications of EMA’s Pharmacovigilance Risk Assessment Committee statement on ivabradine inclusion within ESC guidelines and ivabradine prescribing recommendations

As a result of new data from the SIGNIFY study (1), presented at ESC Congress 2014 and published simultaneously in the New England Journal of Medicine, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has made recommendations aimed at reducing the risk of heart problems, including MI (heart attack) and bradycardia (slow heart rate) in patients prescribed ivabradine for angina. Topics: Clinical pharmacology
Source: ESC News and Press - Category: Cardiology Source Type: news